AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15315844 — intervention group
Group type: COMPARATOR
Intervention: Multi-drug treatment (MDT) with 0.1 ml of distilled water 6 monthly (control group)
Number of subjects: 36
Study 15315844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both immunotherapy groups (groups I and II)
Number of subjects: 36
Study 15315844 — intervention group
Group type: COMPARATOR
Intervention: MDT alone (control group)
Number of subjects: 36
Study 15315844 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy groups (groups I and II)
Number of subjects: 36
Study 11245341 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter directing to visit primary care physician
Number of subjects: 1717
Study 11245341 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter directing to contact clinic directly to schedule a mammogram
Number of subjects: 1717
Study 11245341 — intervention group
Group type: COMPARATOR
Intervention: No letter
Number of subjects: 1717
Study 9093231 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8040775 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (25 micrograms/ml)
Number of subjects: 141
Study 8040775 — intervention group
Group type: COMPARATOR
Intervention: Control (no vancomycin)
Number of subjects: 141
Study 2647033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotazym‐S‐Forte (10,000 BP units of lipase activity per capsule)
Number of subjects: 0
Study 2647033 — intervention group
Group type: COMPARATOR
Intervention: Pancrease (5000 BP units of lipase activity per capsule)
Number of subjects: 0
Study 31886280 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support education model
Number of subjects: 120
Study 31886280 — intervention group
Group type: COMPARATOR
Intervention: Medical staff education model
Number of subjects: 120
Study 31886280 — intervention group
Group type: COMPARATOR
Intervention: Comparison between both groups
Number of subjects: 120
Study 26514001 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 110
Study 26514001 — intervention group
Group type: COMPARATOR
Intervention: Xuanfeijiedu granules
Number of subjects: 110
Study 23829024 — intervention group
Group type: EXPERIMENTAL
Intervention: High flight workload with poor communication signal quality
Number of subjects: 20
Study 23829024 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive communication technology
Number of subjects: 20
Study 23829024 — intervention group
Group type: COMPARATOR
Intervention: Passive headsets
Number of subjects: 20
Study 21072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Active trachoma prevalence in The Gambia
Number of subjects: 8155
Study 21072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Active trachoma prevalence in Tanzania
Number of subjects: 8155
Study 21072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplicor positive prevalence in The Gambia
Number of subjects: 8155
Study 21072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplicor positive prevalence in Tanzania
Number of subjects: 8155
Study 21072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for follicular trachoma (TF) in both countries
Number of subjects: 8155
Study 21072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional risk factors in Tanzania
Number of subjects: 8155
Study 21072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for being Amplicor positive in Tanzania
Number of subjects: 8155
Study 21072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor for being Amplicor positive in The Gambia
Number of subjects: 8155
Study 18372389 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2.4 g/day for 2 years
Number of subjects: 41
Study 18372389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPA treatment)
Number of subjects: 41
Study 16614398 — intervention group
Group type: EXPERIMENTAL
Intervention: EGG (640 mg/d additional dietary cholesterol and 600 microg lutein + zeaxanthin)
Number of subjects: 91
Study 16614398 — intervention group
Group type: COMPARATOR
Intervention: SUB (0 mg/d cholesterol, 0 microg lutein + zeaxanthin)
Number of subjects: 91
Study 14714357 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin Injection (PI) 200 ml by intravenous dripping once a day, starting one week before operation.
Number of subjects: 78
Study 14714357 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 78
Study 14714357 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin Injection (PI)
Number of subjects: 78
Study 10810000 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of oral antivitamin K therapy
Number of subjects: 790
Study 10810000 — intervention group
Group type: COMPARATOR
Intervention: 6 months of oral antivitamin K therapy
Number of subjects: 790
Study 10810000 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 790
Study 8908224 — intervention group
Group type: COMPARATOR
Intervention: Morphine IW, saline IM
Number of subjects: 60
Study 8908224 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline IW, saline IM
Number of subjects: 60
Study 8908224 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline IW, morphine IM
Number of subjects: 60
Study 8908224 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 60
Study 1920184 — intervention group
Group type: EXPERIMENTAL
Intervention: five-week daily exercise training
Number of subjects: 119
Study 1920184 — intervention group
Group type: COMPARATOR
Intervention: exercise training including six sessions of relaxation therapy
Number of subjects: 119
Study 7119271 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure measurement after major surgical interventions
Number of subjects: 55
Study 7119271 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure measurement after preoperative hemodilution
Number of subjects: 55
Study 7119271 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure measurement to avoid albumin administrations
Number of subjects: 55
Study 31927200 — intervention group
Group type: EXPERIMENTAL
Intervention: HBCACR intervention (RehaComTM software)
Number of subjects: 36
Study 31439093 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT with nylon brush and Spectra paste
Number of subjects: 90
Study 31439093 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT with nylon brush and Qartz paste
Number of subjects: 90
Study 31439093 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT with nylon brush and Nupro paste
Number of subjects: 90
Study 31439093 — intervention group
Group type: EXPERIMENTAL
Intervention: Various combinations of pastes and brushes
Number of subjects: 90
Study 31439093 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 90
Study 27299516 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic-behavioral treatment modules of the SELBST program
Number of subjects: 10
Study 27581815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (statin adherence intervention)
Number of subjects: 1906
Study 23289958 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 200 mg d(‐1) for 3 months
Number of subjects: 60
Study 23289958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22522761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplant donor-specific antibodies
Number of subjects: 94
Study 22522761 — intervention group
Group type: COMPARATOR
Intervention: Non-donor-specific antibodies
Number of subjects: 94
Study 22522761 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant donor-specific antibodies
Number of subjects: 94
Study 19176539 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD)
Number of subjects: 14703
Study 19176539 — intervention group
Group type: COMPARATOR
Intervention: No chronic obstructive pulmonary disease (COPD)
Number of subjects: 14703
Study 19176539 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 14703
Study 18000105 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating a significant-other representation in transference
Number of subjects: 0
Study 18000105 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant-other representation activation
Number of subjects: 0
Study 18000105 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant's own ethnic identity activation
Number of subjects: 0
Study 14679386 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cue exposure after a sip of alcohol
Number of subjects: 20
Study 11842916 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg Ginkgo biloba/Panax ginseng combination
Number of subjects: 20
Study 11842916 — intervention group
Group type: EXPERIMENTAL
Intervention: 640 mg Ginkgo biloba/Panax ginseng combination
Number of subjects: 20
Study 11842916 — intervention group
Group type: EXPERIMENTAL
Intervention: 960 mg Ginkgo biloba/Panax ginseng combination
Number of subjects: 20
Study 11842916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10023471 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% oxybuprocaine (benoxinate)
Number of subjects: 14
Study 10023471 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% amethocaine
Number of subjects: 14
Study 10023471 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% proxymetacaine
Number of subjects: 14
Study 7846134 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-wave ultrasound at a dosage of 1.5 W/cm2 for 5 minutes
Number of subjects: 20
Study 7846134 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral forearm with zero ultrasound output)
Number of subjects: 20
Study 2689046 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily)
Number of subjects: 10
Study 2689046 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol (20 mg daily)
Number of subjects: 10
Study 1174242 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyote ingestion
Number of subjects: 57
Study 1174242 — intervention group
Group type: COMPARATOR
Intervention: Huichol Indian controls
Number of subjects: 57
Study 1174242 — intervention group
Group type: COMPARATOR
Intervention: Laboratory controls
Number of subjects: 57
Study 31071137 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced and prolonged Holter‐ECG monitoring
Number of subjects: 398
Study 31071137 — intervention group
Group type: COMPARATOR
Intervention: Routine ECG monitoring
Number of subjects: 398
Study 31071137 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 398
Study 31071137 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 398
Study 28645475 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (intravenous and intracoronary bolus)
Number of subjects: 146
Study 28645475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 26369324 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Number of subjects: 485
Study 22236208 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks loading
Number of subjects: 104
Study 22236208 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks loading
Number of subjects: 104
Study 21354977 — intervention group
Group type: EXPERIMENTAL
Intervention: ON stimulation (3 months)
Number of subjects: 6
Study 21354977 — intervention group
Group type: EXPERIMENTAL
Intervention: ON stimulation (1 year after surgery)
Number of subjects: 6
Study 21354977 — intervention group
Group type: COMPARATOR
Intervention: Cognitive assessment (1 year after surgery)
Number of subjects: 6
Study 21354977 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 6
Study 19934631 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese picture
Number of subjects: 49
Study 19934631 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight picture
Number of subjects: 49
Study 16971295 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Therapy for Adherence to Antiretroviral Treatment (STAART)
Number of subjects: 63
Study 12777339 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 12777339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10675711 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐labelled lactose carrier systems
Number of subjects: 10
Study 10675711 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose carriers
Number of subjects: 10
Study 10675711 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide redispersion
Number of subjects: 10
Study 9583653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention communities (CME training for physicians and staff)
Number of subjects: 660
Study 9583653 — intervention group
Group type: COMPARATOR
Intervention: Comparison communities
Number of subjects: 660
Study 8450129 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual health education
Number of subjects: 3
Study 8450129 — intervention group
Group type: EXPERIMENTAL
Intervention: Group health education
Number of subjects: 3
Study 8450129 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education sessions (third group)
Number of subjects: 3
Study 3551522 — intervention group
Group type: EXPERIMENTAL
Intervention: Today contraceptive sponge
Number of subjects: 0
Study 3551522 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm
Number of subjects: 0
Study 29343528 — intervention group
Group type: EXPERIMENTAL
Intervention: IVTA+VIT group
Number of subjects: 81
Study 29343528 — intervention group
Group type: COMPARATOR
Intervention: VIT group
Number of subjects: 81
Study 27249080 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin XL (4 mg/d to 16 mg/d over 12 days)
Number of subjects: 8
Study 27249080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched capsules)
Number of subjects: 8
Study 24504804 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 250 mg/day
Number of subjects: 70
Study 24504804 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam 7.5 mg/day
Number of subjects: 70
Study 22044976 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetically anchored camera (MAGS)
Number of subjects: 4
Study 22044976 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic camera (LAP)
Number of subjects: 4
Study 22044976 — intervention group
Group type: COMPARATOR
Intervention: Flexible endoscope (ENDO)
Number of subjects: 4
Study 20938880 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX Care®-enhanced routine psychosocial intervention
Number of subjects: 35
Study 20938880 — intervention group
Group type: COMPARATOR
Intervention: Routine psychosocial intervention alone
Number of subjects: 35
Study 18791356 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 130
Study 18791356 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthetic management (STD)
Number of subjects: 130
Study 16129815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 4528
Study 12375378 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-observation measure of parental disciplinary behavior (diary)
Number of subjects: 0
Study 12375378 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit technique (time-out)
Number of subjects: 0
Study 10091825 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage isoproterenol tilt table test
Number of subjects: 111
Study 10091825 — intervention group
Group type: COMPARATOR
Intervention: Passive tilt table test
Number of subjects: 111
Study 8672315 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic alone (lignocaine 10 mg ml‐1 - bupivacaine 3.75 mg ml‐1)
Number of subjects: 24
Study 8672315 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic with adrenaline (5 micrograms ml‐1)
Number of subjects: 24
Study 8672315 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic with hyaluronidase (75 iu ml‐1)
Number of subjects: 24
Study 8672315 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic with adrenaline and hyaluronidase
Number of subjects: 24
Study 2104079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tobramycin
Number of subjects: 84
Study 2104079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 195920 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation treatment
Number of subjects: 359
Study 31189519 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira (insulin degludec plus liraglutide)
Number of subjects: 1012
Study 31189519 — intervention group
Group type: COMPARATOR
Intervention: IGlar U100 (insulin glargine 100 units/mL)
Number of subjects: 1012
Study 31189519 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 1012
Study 28332372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac controlled release (CR) 200 mg once daily
Number of subjects: 100
Study 28332372 — intervention group
Group type: COMPARATOR
Intervention: Aceclofenac 100 mg twice daily
Number of subjects: 100
Study 24229795 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 57
Study 24229795 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 57
Study 23505167 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐h multimodal longitudinal obesity curriculum for residents based on the 5As
Number of subjects: 158
Study 23505167 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study 21609937 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, and lapatinib
Number of subjects: 10
Study 21609937 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 19890073 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) 3 mg/24 h
Number of subjects: 62
Study 19890073 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) 6 mg/24 h
Number of subjects: 62
Study 19890073 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 62
Study 19890073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined STS groups
Number of subjects: 62
Study 16750667 — intervention group
Group type: EXPERIMENTAL
Intervention: MLPA (SALSA P036, P019, and P020 human telomere test kits)
Number of subjects: 95
Study 16750667 — intervention group
Group type: EXPERIMENTAL
Intervention: MLPA (2 kits)
Number of subjects: 95
Study 16750667 — intervention group
Group type: COMPARATOR
Intervention: FISH
Number of subjects: 95
Study 16750667 — intervention group
Group type: EXPERIMENTAL
Intervention: MLPA (1 probe)
Number of subjects: 95
Study 15542048 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol treatment (1 mg 17-beta-estradiol + 1 mg drosperinone or 2 mg drosperinone or 3 mg drosperinone)
Number of subjects: 171
Study 15542048 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol treatment (45 microg 17-beta-estradiol + 30 microg levonorgestrel or 40 microg levonorgestrel)
Number of subjects: 171
Study 15542048 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol treatment
Number of subjects: 171
Study 15542048 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol treatment
Number of subjects: 171
Study 15542048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and transdermal estradiol therapy
Number of subjects: 171
Study 16136910 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling measures including well-ventilation, washing clothes and bedclothes, catching dust frequently, exposing clothing or bedclothes in the sun
Number of subjects: 43
Study 16136910 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling measures
Number of subjects: 43
Study 16136910 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 43
Study 9308743 — intervention group
Group type: EXPERIMENTAL
Intervention: Napsagatran 5 mg/h
Number of subjects: 110
Study 9308743 — intervention group
Group type: EXPERIMENTAL
Intervention: Napsagatran 9 mg/h
Number of subjects: 110
Study 9308743 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (control)
Number of subjects: 110
Study 8315426 — intervention group
Group type: COMPARATOR
Intervention: Continuous bladder irrigation with 200 mL/h of normal saline
Number of subjects: 200
Study 8315426 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion mesna at 100% of the cyclophosphamide dose
Number of subjects: 200
Study 3455568 — intervention group
Group type: EXPERIMENTAL
Intervention: Imotest
Number of subjects: 105
Study 3455568 — intervention group
Group type: COMPARATOR
Intervention: Mantoux test (10 I.U.)
Number of subjects: 105
Study 29679770 — intervention group
Group type: EXPERIMENTAL
Intervention: ETRIC form
Number of subjects: 198
Study 29679770 — intervention group
Group type: COMPARATOR
Intervention: Standard consent form
Number of subjects: 198
Study 27135916 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10(9) CFU/g each) for 8 weeks
Number of subjects: 60
Study 27135916 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules
Number of subjects: 60
Study 27135916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose capsules) for 8 weeks
Number of subjects: 60
Study 24964227 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (two group‐mediated workshop sessions based on social cognitive theory)
Number of subjects: 141
Study 24964227 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 141
Study 22575038 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss intervention
Number of subjects: 123
Study 21246850 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric-moxibustion at Baihui (GV 20) for 20 and 30 minutes
Number of subjects: 20
Study 21246850 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric-moxibustion at Shenque (CV 8) for 10, 20 and 30 minutes
Number of subjects: 20
Study 18487781 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid electronic-paper environment
Number of subjects: 35
Study 18487781 — intervention group
Group type: COMPARATOR
Intervention: Paper patient record
Number of subjects: 35